NASDAQ:CRMD CorMedix (CRMD) Stock Price, News & Analysis $8.90 +0.61 (+7.36%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About CorMedix Stock (NASDAQ:CRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CorMedix alerts:Sign Up Key Stats Today's Range$8.28▼$9.0350-Day Range$3.64▼$8.9052-Week Range$2.57▼$9.03Volume1.23 million shsAverage Volume616,770 shsMarket Capitalization$489.14 millionP/E RatioN/ADividend YieldN/APrice Target$12.60Consensus RatingBuy Company OverviewCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Read More… Next opportunity for crypto millions (Ad)"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive gains. This year could be off the charts. Don't let this opportunity pass you by. In crypto, timing is everything. Go here to discover the #1 crypto set to dominate Uptober. CorMedix Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks19th Percentile Overall ScoreCRMD MarketRank™: CorMedix scored higher than 19% of companies evaluated by MarketBeat, and ranked 903rd out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCorMedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorMedix has only been the subject of 4 research reports in the past 90 days.Read more about CorMedix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CorMedix are expected to grow in the coming year, from ($0.58) to $0.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CorMedix is -9.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CorMedix is -9.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorMedix has a P/B Ratio of 6.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CorMedix's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.89% of the outstanding shares of CorMedix have been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in CorMedix has recently increased by 2.67%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorMedix does not currently pay a dividend.Dividend GrowthCorMedix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.89% of the outstanding shares of CorMedix have been sold short.Short Interest Ratio / Days to CoverCorMedix has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in CorMedix has recently increased by 2.67%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 11 people have searched for CRMD on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CorMedix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of CorMedix is held by insiders.Percentage Held by InstitutionsOnly 34.18% of the stock of CorMedix is held by institutions.Read more about CorMedix's insider trading history. Receive CRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter. Email Address CRMD Stock News HeadlinesCorMedix Inc. (NASDAQ:CRMD): When Will It Breakeven?September 25, 2024 | finance.yahoo.comAkero Therapeutics, Inc. (0K4.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comNext opportunity for crypto millions"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive gains. This year could be off the charts. Don't let this opportunity pass you by. In crypto, timing is everything. October 6, 2024 | Crypto 101 Media (Ad)CorMedix Inc. to Present at the Cantor Global Healthcare ConferenceSeptember 13, 2024 | globenewswire.comBuy Rating on Cormedix Affirmed Amidst DefenCath’s Strong Market Entry and Growth ProspectsSeptember 9, 2024 | markets.businessinsider.comCorMedix Inc. Announces New Commercial AgreementSeptember 9, 2024 | globenewswire.comCormedix Inc (19KA.SG)August 28, 2024 | uk.finance.yahoo.comRodman & Renshaw Initiates Coverage of CorMedix (CRMD) with Buy RecommendationAugust 27, 2024 | msn.comSee More Headlines CRMD Stock Analysis - Frequently Asked Questions How have CRMD shares performed this year? CorMedix's stock was trading at $3.76 at the start of the year. Since then, CRMD stock has increased by 136.7% and is now trading at $8.90. View the best growth stocks for 2024 here. How were CorMedix's earnings last quarter? CorMedix Inc. (NASDAQ:CRMD) announced its earnings results on Wednesday, August, 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. The business had revenue of $0.81 million for the quarter, compared to analysts' expectations of $0.75 million. When did CorMedix's stock split? CorMedix's stock reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Who are CorMedix's major shareholders? Top institutional investors of CorMedix include SG Americas Securities LLC (0.03%). Insiders that own company stock include Myron Kaplan and Matthew T David. View institutional ownership trends. How do I buy shares of CorMedix? Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CorMedix own? Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV) and QUALCOMM (QCOM). Company Calendar Last Earnings8/14/2024Today10/05/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRMD CUSIPN/A CIK1410098 Webwww.cormedix.com Phone(908) 517-9500Fax908-429-4307Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$12.60 High Stock Price Target$19.00 Low Stock Price Target$9.00 Potential Upside/Downside+41.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,340,000.00 Net MarginsN/A Pretax Margin-6,763.03% Return on Equity-82.50% Return on Assets-71.00% Debt Debt-to-Equity RatioN/A Current Ratio4.79 Quick Ratio4.43 Sales & Book Value Annual Sales$806,119.00 Price / Sales606.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book6.95Miscellaneous Outstanding Shares54,959,000Free Float52,980,000Market Cap$489.14 million OptionableOptionable Beta1.61 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CRMD) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.